Y 25510
Latest Information Update: 26 Jun 2002
At a glance
- Originator Mitsubishi Pharma Corporation
- Class
- Mechanism of Action Interleukin 1 beta stimulants; Interleukin 6 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Leucopenia; Thrombocytopenia
Most Recent Events
- 26 Jun 2002 No development reported - Phase-I for Leucopenia in Japan (unspecified route)
- 26 Jun 2002 No development reported - Phase-I for Thrombocytopenia in Japan (unspecified route)
- 30 Mar 1998 Phase-I clinical trials for Leucopenia in Japan (Unknown route)